Longeveron Inc. (LGVN)
NASDAQ (CM) NASDAQ (CM) Primary Summary
Longeveron Inc. (LGVN) Q1 2026 Earnings Call Transcript
Longeveron Inc. (LGVN) Q1 2026 Earnings Call Transcript
Longeveron Inc. (LGVN) Q4 2025 Earnings Call Transcript
Longeveron Inc. (LGVN) Q4 2025 Earnings Call Transcript
Longeveron Inc. (LGVN) Q3 2025 Earnings Call Transcript
Longeveron Inc. ( LGVN ) Q3 2025 Earnings Call November 4, 2025 4:30 PM EST Company Participants Than Powell - Interim CEO & Director Nataliya Agafonova - Chief Medical Officer Devin Blass - CTO & Senior VP of Chemistry, Manufacturing, and Controls Lisa Locklear - CFO, Executive VP & Treasurer Joshua Hare - Co-Founder, Chief Science Officer & Executive Chairman Conference Call Participants Derek Cole Raghuram Selvaraju - H.C. Wainwright & Co, LLC, Research Division Boobalan Pachaiyappan - ROTH Capital Partners, LLC, Research Division Michael Okunewitch - Maxim Group LLC, Research Division Presentation Operator Greetings, and welcome to the Longeveron 2025 Q3 Financial Results and Business Update Call.
Longeveron Inc. (LGVN) FAQ
What is the stock price today?
On which exchange is it traded?
What is its stock symbol?
Does it pay dividends? What is the current yield?
What is its market cap?
Has Longeveron Inc. ever had a stock split?
Longeveron Inc. Profile
| Biotechnology Industry | Healthcare Sector | Stephen H. Willard CEO | NASDAQ (CM) Exchange | 54303L104 CUSIP |
| US Country | 25 Employees | - Last Dividend | 27 Mar 2024 Last Split | 12 Feb 2021 IPO Date |
Overview
Longeveron Inc. represents a pioneering force in the biotechnological sector, focusing on developing innovative cellular therapies aimed at addressing both aging-related and life-threatening health conditions. Since its establishment in 2014, with headquarters based in Miami, Florida, Longeveron has positioned itself at the forefront of clinical-stage research in the United States and Japan. The company's dedication to leveraging stem cell technology underscores its commitment to advancing medical research and providing new avenues for therapeutics in fields that are critically in need of innovation.
Products and Services
At the heart of Longeveron's expansive product pipeline is LOMECEL-B, an advanced investigational cellular therapy product that represents the company's principal focus. Below are details regarding their flagship product and its applications:
- LOMECEL-B: This allogeneic mesenchymal stem cell (MSC) formulation is carefully sourced from the bone marrow of young, healthy adult donors. LOMECEL-B is underpinned by its potential for reparative and regenerative properties, making it a cornerstone of Longeveron's clinical endeavors. The company is actively conducting several stages of clinical trials to explore the efficacy and safety of LOMECEL-B across various medical conditions and indications, including:
- Aging-Related Frailty: The application of LOMECEL-B in combating aging-related frailty illustrates Longeveron's dedication to improving the quality of life for the elderly population. This indication is currently exploring the extent to which LOMECEL-B can enhance physical function and health span in older individuals.
- Alzheimer's Disease: Alzheimer's disease represents a significant challenge in the realm of neurodegenerative disorders. Longeveron's clinical trials aim to ascertain LOMECEL-B's potential in moderating the effects of Alzheimer's, offering hope for a disease that currently has limited therapeutic options.
- Hypoplastic Left Heart Syndrome (HLHS): This severe congenital heart defect affects newborns and is currently being addressed through Phase 1 and Phase 2a clinical trials of LOMECEL-B. The trials aim to evaluate the safety and efficacy of the product in improving the outcomes and survival rates of affected infants.
